nach oben

Clinical and Experimental Nephrology

Erschienen in:

01.10.2009 | Review Article

Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists

verfasst von: Jun Wada, Hirofumi Makino

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

The most problematic issue in clinical nephrology worldwide is the relentless and progressive increase in patients with end-stage renal disease (ESRD). Diabetic nephropathy has considerable impact on society in the areas of public health and social economy; many scientists are involved in research for the elucidation of the pathogenesis of diabetic nephropathy and for the prevention and cure of the disease. In contrast, diabetic nephropathy was a neglected or ignored disease in the historical era, and few dedicated physicians recognized the disease process of diabetic nephropathy. In this review, we look back on the history of basic and clinical research on diabetic nephropathy and survey the recent progress of the research, especially focusing on the contribution of Japanese scientists.

Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11(2):156–63.CrossRefPubMed

Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11(1):41–50.CrossRefPubMed

Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) study. Diabetologia. 2005;48(1):17–26.CrossRefPubMed

Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057–63.CrossRefPubMed

Henschen F. On the term diabetes in the works of Aretaeus and Galen. Med Hist. 1969;13(2):190–2.CrossRefPubMedPubMedCentral

Schena FP. Domenico Cotugno and his interest in proteinuria. Am J Nephrol. 1994;14(4–6):325–9.CrossRefPubMed

Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy’s Hosp Rep. 1836;1:336.

De Santo NG, Lamendola MG. Luciano Armanni. Am J Nephrol. 1994;14(4–6):448–51.CrossRefPubMed

Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12:83–97.PubMedPubMedCentral

10.

Murakami R. Beitrag zum Kennttniss der Veranderung des Nierenkorperchens beim diabetes mellitus. Trans Soc Path Jpn. 1936;26:657.

11.

Spuhler O, Zollinger HU. Die diabetische glomerulosklerose. Deutsch Arch Klin Med. 1943;190:321.

12.

Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Kark RM. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959;38:321–67.CrossRef

13.

Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Maduros W, Kark RM. Structure and function in diabetic nephropathy; the importance of diffuse glomerulosclerosis. Diabetes. 1959;8(4):251–6.CrossRefPubMed

14.

Østerby R, Gundersen HJ. Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia. 1975;11(3):225–9.CrossRefPubMed

15.

Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78.CrossRefPubMed

16.

Nakamoto Y, Takazakura E, Hayakawa H, Kawai K, Dohi K, Fujioka M, et al. Intrarenal microaneurysms in diabetic nephropathy. Lab Invest. 1980;42(4):433–9.PubMed

17.

Saito Y, Kida H, Takeda S, Yoshimura M, Yokoyama H, Koshino Y, et al. Mesangiolysis in diabetic glomeruli: its role in the formation of nodular lesions. Kidney Int. 1988;34(3):389–96.CrossRefPubMed

18.

Yajima G. A histopathological study on diabetic nephropathy—light and electron microscopic observations. Acta Pathol Jpn. 1976;26(1):47–62.PubMed

19.

Nishi S, Ueno M, Hisaki S, Iino N, Iguchi S, Oyama Y, et al. Ultrastructural characteristics of diabetic nephropathy. Med Electron Microsc. 2000;33(2):65–73.CrossRefPubMed

20.

Hayashi H, Karasawa R, Inn H, Saitou T, Ueno M, Nishi S, et al. An electron microscopic study of glomeruli in Japanese patients with non-insulin dependent diabetes mellitus. Kidney Int. 1992;41(4):749–57.CrossRefPubMed

21.

Suzuki Y, Ueno M, Hayashi H, Nishi S, Satou H, Karasawa R, et al. A light microscopic study of glomerulosclerosis in Japanese patients with noninsulin-dependent diabetes mellitus: the relationship between clinical and histological features. Clin Nephrol. 1994;42(3):155–62.PubMed

22.

Ota Z, Shikata K, Ota K. Nephrotic tunnels in glomerular basement membrane as revealed by a new electron microscopic method. J Am Soc Nephrol. 1994;4(12):1965–73.PubMed

23.

Hironaka K, Makino H, Yamasaki Y, Ota Z. Renal basement membranes by ultrahigh resolution scanning electron microscopy. Kidney Int. 1993;43(2):334–45.CrossRefPubMed

24.

Makino H, Yamasaki Y, Haramoto T, Shikata K, Hironaka K, Ota Z, et al. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest. 1993;68(1):45–55.PubMed

25.

Moriya T, Ohno S, Nakazawa K, Shigematsu H, Yajima Y. Ultrastructural study of glomerular basement membrane in diabetic rats by quick-freezing and deep-etching method. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(2):107–14.CrossRefPubMed

26.

Moriya T, Ohno S, Tanaka K, Fujita Y. Clinical applications of the quick-freezing and deep-etching method to human diabetic nephropathy. J Electron Microsc (Tokyo). 2006;55(2):69–73.CrossRef

27.

Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 1997;52(1):111–9.CrossRefPubMed

28.

Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes. 1995;44(10):1233–8.CrossRefPubMed

29.

Toyoda M, Suzuki D, Honma M, Uehara G, Sakai T, Umezono T, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int. 2004;66(3):1107–14.CrossRefPubMed

30.

Kikkawa R, Umemura K, Haneda M, Arimura T, Ebata K, Shigeta Y. Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes. 1987;36(2):240–3.CrossRefPubMed

31.

Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes. 1997;46(5):847–53.CrossRefPubMed

32.

Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;14(3):439–47.CrossRefPubMed

33.

Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes. 2000;49(6):1022–32.CrossRefPubMed

34.

Ishida T, Haneda M, Maeda S, Koya D, Kikkawa R. Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase. Diabetes. 1999;48(3):595–602.CrossRefPubMed

35.

Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836–42.CrossRefPubMed

36.

Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int. 1995;48(2):517–26.CrossRefPubMed

37.

Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 1997;100(12):2995–3004.CrossRefPubMedPubMedCentral

38.

Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 1994;343(8912):1519–22.CrossRefPubMed

39.

Mitsuhashi T, Nakayama H, Itoh T, Kuwajima S, Aoki S, Atsumi T, et al. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes. 1993;42(6):826–32.CrossRefPubMed

40.

Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem. 2002;277(23):20309–15.CrossRefPubMed

41.

Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108(2):261–8.CrossRefPubMedPubMedCentral

42.

Uesugi N, Sakata N, Horiuchi S, Nagai R, Takeya M, Meng J, et al. Glycoxidation-modified macrophages and lipid peroxidation products are associated with the progression of human diabetic nephropathy. Am J Kidney Dis. 2001;38(5):1016–25.CrossRefPubMed

43.

Fukuhara-Takaki K, Sakai M, Sakamoto Y, Takeya M, Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J Biol Chem. 2005;280(5):3355–64.CrossRefPubMed

44.

Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y, et al. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int. 1996;49(4):1120–6.CrossRefPubMed

45.

Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest. 1993;92(6):2597–601.CrossRefPubMedPubMedCentral

46.

Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 1999;55(2):465–75.CrossRefPubMed

47.

Haneda M, Kikkawa R, Koya D, Uzu T, Maeda S, Togawa M, et al. Alteration of mesangial response to ANP and angiotensin II by glucose. Kidney Int. 1993;44(3):518–26.CrossRefPubMed

48.

Haneda M, Kikkawa R, Maeda S, Togawa M, Koya D, Horide N, et al. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int. 1991;40(2):188–94.CrossRefPubMed

49.

Kikkawa R, Haneda M, Sakamoto K, Koya D, Shikano T, Nakanishi S, et al. Antagonist for atrial natriuretic peptide receptors ameliorates glomerular hyperfiltration in diabetic rats. Biochem Biophys Res Commun. 1993;193(2):700–5.CrossRefPubMed

50.

Makino H, Mukoyama M, Mori K, Suganami T, Kasahara M, Yahata K, et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia. 2006;49(10):2514–24.CrossRefPubMed

51.

Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia. 1998;41(12):1426–34.CrossRefPubMed

52.

Hiragushi K, Wada J, Eguchi J, Matsuoka T, Yasuhara A, Hashimoto I, et al. The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats. Kidney Int. 2004;65(2):540–50.CrossRefPubMed

53.

Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 2004;53(7):1831–40.CrossRefPubMed

54.

Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005;54(10):2891–903.CrossRefPubMed

55.

Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, Kitayama H, et al. 2-(8-hydroxy-6-methoxy-1-oxo-1h–2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006;55(5):1232–42.CrossRefPubMed

56.

Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis. 1993;21(5):480–5.CrossRefPubMed

57.

Sugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kushiro M, et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes. 1997;46(12):2075–81.CrossRefPubMed

58.

Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003;52(10):2586–93.CrossRefPubMed

59.

Usui HK, Shikata K, Sasaki M, Okada S, Matsuda M, Shikata Y, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes. 2007;56(2):363–72.CrossRefPubMed

60.

Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003;18(2):265–72.CrossRefPubMed

61.

Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-{kappa}B activation. Am J Physiol Renal Physiol. 2007;292(4):F1141–50.CrossRefPubMed

62.

Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, et al. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol. 2005;16(11):3326–38.CrossRefPubMed

63.

Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, Nishishita S, et al. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia. 2005;48(11):2402–11.CrossRefPubMed

64.

Miyata T, Nangaku M, Suzuki D, Inagi R, Uragami K, Sakai H, et al. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J Clin Invest. 1998;102(4):828–36.CrossRefPubMedPubMedCentral

65.

Inagi R, Yamamoto Y, Nangaku M, Usuda N, Okamato H, Kurokawa K, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes. 2006;55(2):356–66.CrossRefPubMed

66.

Wada J, Kanwar YS. Characterization of mammalian translocase of inner mitochondrial membrane (Tim44) isolated from diabetic newborn mouse kidney. Proc Natl Acad Sci USA. 1998;95(1):144–9.CrossRefPubMedPubMedCentral

67.

Yang Q, Dixit B, Wada J, Tian Y, Wallner EI, Srivastva SK, et al. Identification of a renal-specific oxido-reductase in newborn diabetic mice. Proc Natl Acad Sci USA. 2000;97(18):9896–901.CrossRefPubMedPubMedCentral

68.

Matsuoka T, Wada J, Hashimoto I, Zhang Y, Eguchi J, Ogawa N, et al. Gene delivery of Tim44 reduces mitochondrial superoxide production and ameliorates neointimal proliferation of injured carotid artery in diabetic rats. Diabetes. 2005;54(10):2882–90.CrossRefPubMed

69.

Zhang Y, Wada J, Hashimoto I, Eguchi J, Yasuhara A, Kanwar YS, et al. Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. J Am Soc Nephrol. 2006;17(4):1090–101.CrossRefPubMed

70.

Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006;55(6):1666–77.CrossRefPubMed

71.

Nagai K, Arai H, Yanagita M, Matsubara T, Kanamori H, Nakano T, et al. Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem. 2003;278(20):18229–34.CrossRefPubMed

72.

Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 2005;68(2):552–61.CrossRefPubMed

73.

Yanagita M. Gas6, warfarin, and kidney diseases. Clin Exp Nephrol. 2004;8(4):304–9.CrossRefPubMed

74.

Yanagita M. The role of the vitamin K-dependent growth factor Gas6 in glomerular pathophysiology. Curr Opin Nephrol Hypertens. 2004;13(4):465–70.CrossRefPubMed

75.

Suganami T, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Sawai K, et al. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J. 2005;19(1):127–9.CrossRefPubMed

76.

Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes. 2005;54(4):1171–8.CrossRefPubMed

77.

Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, et al. Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes. 2003;52(11):2848–53.CrossRefPubMed

78.

Hayashi Y, Makino H, Ota Z. Serum and urinary concentrations of type IV collagen and laminin as a marker of microangiopathy in diabetes. Diabet Med. 1992;9(4):366–70.CrossRefPubMed

79.

Okonogi H, Nishimura M, Utsunomiya Y, Hamaguchi K, Tsuchida H, Miura Y, et al. Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol. 2001;55(5):357–64.PubMed

80.

Tomino Y, Suzuki S, Azushima C, Shou I, Iijima T, Yagame M, et al. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal. 2001;15(4):188–92.CrossRefPubMed

81.

Yoshikawa R, Wada J, Seiki K, Matsuoka T, Miyamoto S, Takahashi K, et al. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;76(3):358–67.CrossRefPubMed

82.

Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005;28(11):2728–32.CrossRefPubMed

83.

Nakamura T, Sugaya T, Koide H. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia. 2007;50(2):490–2.CrossRefPubMed

84.

Suzuki K, Babazono T, Murata H, Iwamoto Y. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy. Diabetes Care. 2005;28(8):2038–9.CrossRefPubMed

85.

Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313(26):1617–20.CrossRefPubMed

86.

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–17.CrossRefPubMed

87.

Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–8.CrossRefPubMed

88.

Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007;30(6):1581–3.CrossRefPubMed

89.

Araki SI, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes mellitus. Diabetes. 2007;56(6):1727–30.CrossRefPubMed

Titel: Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists
verfasst von: Jun Wada
Hirofumi Makino
Publikationsdatum: 01.10.2009
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 5/2009
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-009-0175-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

Hemolytic uremic syndrome due to homozygous factor H deficiency

Six-year dialysis freedom in end-stage renal disease

Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy

Physicians make different decisions from nephrologists at serum creatinine 2.0 mg/dl

O-linked oligosaccharides of the IgA1 hinge region: roles of its aberrant structure in the occurrence and/or progression of IgA nephropathy